|Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article.|
1. Tafluprost (Zioptan) - a new topical prostaglandin for glaucoma. Med Lett Drugs Ther 2012; 54:31.
2. K Inoue et al. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma 2012; August 29 (epub).
3. JH Liu et al. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 2010; 117:2075.
4. S Arthur and LB Cantor. Update on the role of alpha-agonists in glaucoma management. Exp Eye Res 2011; 93:271.
5. RJ Casson et al. Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study. J Glaucoma 2009; 18:582.
6. LP Aiello. Targeting intraocular neovascularization and edema – one drop at a time. N Engl J Med 2008; 359:967.
7. Pegaptanib sodium (Macugen) for macular degeneration. Med Lett Drugs Ther 2005; 47:55.
8. Ranibizumab (Lucentis) for macular degeneration. Med Lett Drugs Ther 2006; 48:85.
9. PJ Rosenfeld et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419.
10. CD Regillo et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145:239.
11. BA Frost and MA Kainer. Safe preparation and administration of intravitreal bevacizumab injections. N Engl J Med 2011; 365:2238.
12. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897.
13. CATT Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119:1388.
14. Aflibercept (Eylea) for age-related macular degeneration. Med Lett Drugs Ther 2012; 54:9.
15. S Day et al. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol 2011; 152:266.
16. FG Holz et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011; 118:663.
17. Photodynamic therapy with verteporfin (Visudyne) for macular degeneration. Med Lett Drugs Ther 2000; 42:81.
18. NM Bressler. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 2001; 119:198.
19. M Azab et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005; 123:448.
20. JB Jonas et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative non-randomized study. Eye (Lond) 2005; 19:163.
21. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119:1417.
22. Nutritional support for macular degeneration. Med Lett Drugs Ther 2010; 52:63.
23. The ATBC Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994; 330:1029.
24. GS Omenn et al. Effects of a combination of beta carotene and vitamin Aon lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150.
25. ER Miller 3rd et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37.
26. I Bairati et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer 2006; 119:2221.
27. W Haas et al. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol 2011; 5:1369.
28. Opthalmic azithromycin (AzaSite). Med Lett Drugs Ther 2008; 50:11.
29. Ophthalmic Besifloxacin (Besivance). Med Lett Drugs Ther 2009; 51:101.
30. WB Jackson. Management of dysfunctional tear syndrome: a Canadian consensus. Can J Ophthalmol 2009; 44:385.
31. AH Wander and BH Koffler. Extending the duration of tear film protection in dry eye syndrome: review and retrospective case series study of the hydroxypropyl cellulose ophthalmic insert. Ocul Surf 2009; 7:154.
32. Ophthalmic cyclosporine (Restasis) for dry eye disease. Med Lett Drug Ther 2003; 45:42.
33. HD Perry et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol 2008; 126:1046.